Kephera develops rapid tests for infectious diseases using novel immunochemistry in point-of-care format. They use their proprietary assay technology based on principles of particle interaction combined with a simple device, which together enable rapid detection of specific antibodies or antigens associated with the target pathogen. This applicable to a wide range of disease targets and applications. Kephera’s expertise extends from antigen discovery using microarrays and peptide libraries to assay development, clinical studies and validation. They collaborate with academic research institutions in the U.S. and internationally, along with researchers at the National Institutes of Health (NIH) and the Centers for Disease Control and Prevention (CDC) .